Responses
Rheumatology
Protocol
Belimumab after B cell depletion therapy in patients with systemic lupus erythematosus (BEAT Lupus) protocol: a prospective multicentre, double-blind, randomised, placebo-controlled, 52-week phase II clinical trial
Compose a Response to This Article
Other responses
No responses have been published for this article.